BibTex RIS Kaynak Göster

-

Yıl 2007, Cilt: 20 Sayı: 2, 104 - 109, 25.06.2015

Öz

-

Kaynakça

  • 1. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in United States. Ann Intern Med 1999;130:545- 553.
  • 2. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-990.
  • 3. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
  • 4. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-1049.
  • 5. Gardy D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
  • 6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
  • 7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
  • 8. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2002;360:942-944.
  • 9. Tattersall MH. Risks and benefits of postmenopausal combined hormone replacement therapy. Med J Aust 2002;177:173-174.
  • 10. Gorman C, Park A. The truth about hormones. Time. Health and Medicine Section. July 22, 2002.
  • 11. LeBanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and metanalysis. JAMA 2001;285:1489-1499.
  • 12. Travers C, O’Neill SM, Khoo SK, King R. Hormones down under: hormone therapy use after the Women’s Health Initiative. Aust N Z J Obstet Gynaecol 2006; 46:330-335.
  • 13. Clanget C, Hinke V, Lange S, et al. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 2005;113:529-533.
  • 14. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
  • 15. Leung KY, Ling M, Tang GW. Use of hormone replacement therapy in the Hong Kong public health sector after the Women’s Health Initiative trial. Maturitas 2005;52(3-4):277-285.
  • 16. Blümel JE, Castelo-Branco C, Chedraui PA, et al. Patient’s and clinician’s attitudes after the Women’s Health Initiative study. Menopause 2005;11:57-61.
  • 17. Heitmann C, Greiser E, Dören M. The impact of the Women’s Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 2005;12:405-411.
  • 18. Karakoç B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102- 106.
  • 19. Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228- 234.
  • 20. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause 2004;11:11-33.
  • 21. Hoffmann M, Hammar M, Kjellgren KI, et al. Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;16;52:11- 17.
  • 22. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske E. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140(3):184-188.
  • 23. Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J Gen Intern Med 2005;20:1026-1031.
  • 24. Ettinger B, Grady D, Tosteson AN, et al. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.

TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ

Yıl 2007, Cilt: 20 Sayı: 2, 104 - 109, 25.06.2015

Öz

Amaç:Women’s Health Initiative (WHI) çalışmasının yayınlanmasının takiben hormon tedavisinin (HT) sürdürülmesi veya kesilmesine olan etkisini incelemek. Materyal ve Metod: Çalışma Temmuz 2002 ile Temmuz 2005 tarihleri arasında 816 postmenopozal kadın ile gerçekleştirildi. Hastalara sosyo-demografik özellikleri, HT kullanım bilgileri, WHI çalışması hakkında bilgiler soruldu. Bulgular: Kadınların ortalama yaşları 49,3±3,6 ve cevap oranları %54,7 idi. Katılımcıların %22,1'i HT almakta iken, %77,9'i HT kullanmamaktaydı. Kadınların üniversite mezunu, lise, ortaokul ve ilkokul mezunu olanları sırasıyla 131, 99, 60, 157 şeklinde idi. İlkokul mezunlarında HT kullanım oranı %25,üniversite mezunlarında %20 olması tedavinin eğitim durumundan etkilenmediğini göstermekte idi. 2002 yılının ikinci yarısında HT başlama oranı 18,6%, 2003'te % 30,5 şeklinde olup 2004 yılında %21,5'e, 2005 yılında %20,9 oranına geriledi. WHI çalışmasından sonra HT başlanan kadınlarda tedaviye devam oranı %41'di. Sonuç: Çalışmamız WHI sonuçlarının menopoz ünitemize HT devamı ve kesilmesi üzerine etkide bulunduğunu göstermektedir. WHI hakkında bilginin en çok medyadan veya doktorlardan elde edildiği ve HT devamı veya kesilmesi üzerine belirgin etkisi olduğu saptandı.

Anahtar Kelimeler: Hormon tedavisi, WHI, Menopoz

Kaynakça

  • 1. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in United States. Ann Intern Med 1999;130:545- 553.
  • 2. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173:982-990.
  • 3. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
  • 4. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-1049.
  • 5. Gardy D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
  • 6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
  • 7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
  • 8. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2002;360:942-944.
  • 9. Tattersall MH. Risks and benefits of postmenopausal combined hormone replacement therapy. Med J Aust 2002;177:173-174.
  • 10. Gorman C, Park A. The truth about hormones. Time. Health and Medicine Section. July 22, 2002.
  • 11. LeBanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and metanalysis. JAMA 2001;285:1489-1499.
  • 12. Travers C, O’Neill SM, Khoo SK, King R. Hormones down under: hormone therapy use after the Women’s Health Initiative. Aust N Z J Obstet Gynaecol 2006; 46:330-335.
  • 13. Clanget C, Hinke V, Lange S, et al. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 2005;113:529-533.
  • 14. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
  • 15. Leung KY, Ling M, Tang GW. Use of hormone replacement therapy in the Hong Kong public health sector after the Women’s Health Initiative trial. Maturitas 2005;52(3-4):277-285.
  • 16. Blümel JE, Castelo-Branco C, Chedraui PA, et al. Patient’s and clinician’s attitudes after the Women’s Health Initiative study. Menopause 2005;11:57-61.
  • 17. Heitmann C, Greiser E, Dören M. The impact of the Women’s Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 2005;12:405-411.
  • 18. Karakoç B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102- 106.
  • 19. Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228- 234.
  • 20. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause 2004;11:11-33.
  • 21. Hoffmann M, Hammar M, Kjellgren KI, et al. Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;16;52:11- 17.
  • 22. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske E. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140(3):184-188.
  • 23. Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J Gen Intern Med 2005;20:1026-1031.
  • 24. Ettinger B, Grady D, Tosteson AN, et al. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
Toplam 24 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Mithat Erenus Bu kişi benim

Meltem Uygur Bu kişi benim

Pınar Yörük Bu kişi benim

Fatih Durmuşoğlu Bu kişi benim

Yayımlanma Tarihi 25 Haziran 2015
Yayımlandığı Sayı Yıl 2007 Cilt: 20 Sayı: 2

Kaynak Göster

APA Erenus, M., Uygur, M., Yörük, P., Durmuşoğlu, F. (2015). TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ. Marmara Medical Journal, 20(2), 104-109.
AMA Erenus M, Uygur M, Yörük P, Durmuşoğlu F. TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ. Marmara Med J. Ağustos 2015;20(2):104-109.
Chicago Erenus, Mithat, Meltem Uygur, Pınar Yörük, ve Fatih Durmuşoğlu. “TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ”. Marmara Medical Journal 20, sy. 2 (Ağustos 2015): 104-9.
EndNote Erenus M, Uygur M, Yörük P, Durmuşoğlu F (01 Ağustos 2015) TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ. Marmara Medical Journal 20 2 104–109.
IEEE M. Erenus, M. Uygur, P. Yörük, ve F. Durmuşoğlu, “TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ”, Marmara Med J, c. 20, sy. 2, ss. 104–109, 2015.
ISNAD Erenus, Mithat vd. “TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ”. Marmara Medical Journal 20/2 (Ağustos 2015), 104-109.
JAMA Erenus M, Uygur M, Yörük P, Durmuşoğlu F. TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ. Marmara Med J. 2015;20:104–109.
MLA Erenus, Mithat vd. “TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ”. Marmara Medical Journal, c. 20, sy. 2, 2015, ss. 104-9.
Vancouver Erenus M, Uygur M, Yörük P, Durmuşoğlu F. TÜRKİYEDE TERSİYER BİR MENOPOZ MERKEZİNDE WOMEN’S HEALTH İNİTİATİVE ÇALIŞMASININ HORMON TEDAVİSİ DEVAMI VEYA KESİLMESİNE OLAN ETKİSİ. Marmara Med J. 2015;20(2):104-9.